Key result
Higher NT-proBNP/BNP ratio linked to ~5% increased MACE risk in CKD stages 4 and 5.
Why the study?
BNP and NT-proBNP levels are influenced by several factors, and their impacts in patients with chronic kidney disease remain unclear.
Does the NT-proBNP/BNP ratio predict cardiovascular events in patients with advanced chronic kidney disease?
Observational (n=1,036)
No
Does the NT-proBNP/BNP ratio predict cardiovascular events in patients with advanced chronic kidney disease?
Effect estimate: HR 1.054 (95% CI 1.017-1.092)
p-value: p=0.005
In patients with advanced chronic kidney disease, the NT-proBNP/BNP ratio is a useful independent predictor of cardiovascular events, overcoming the confounding effect of renal dysfunction on individual natriuretic peptide levels.
No takes yet. Share an insight, caveat, or question.
May aid risk stratification in advanced CKD; hypothesis-generating and should not yet change practice.
Fujii et al. (2025) conducted an observational in Chronic kidney disease (n=1,036). NT-proBNP/BNP ratio vs. Lower NT-proBNP/BNP ratio was evaluated on Major adverse cardiovascular events (MACE) in CKD stages 4 and 5 (HR 1.054, 95% CI 1.017-1.092, p=0.005). A higher NT-proBNP/BNP ratio was significantly associated with an increased risk of major adverse cardiovascular events (HR 1.054) in patients with chronic kidney disease stages 4 and 5.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: